MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-17-2025
AIM ImmunoTech Accounts Receivables 2011-2026 | AIM
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables AIM ImmunoTech
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 34 K | 44 K | 235 K | 24 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 235 K | 24 K | 84.2 K |
Quarterly Accounts Receivables AIM ImmunoTech
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 1.18 M | 48 K | 33 K | - | 1.68 M | - | - | - | - | 28 K | 28 K | 34 K | 34 K | 34 K | 34 K | 34 K | 44 K | 44 K | 44 K | 44 K | 235 K | 235 K | 235 K | 235 K | 24 K | 24 K | 24 K | 24 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.68 M | 24 K | 190 K |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K |  USA |
 |
ADMA Biologics
ADMA
|
158 M | $ 16.49 | -0.3 % | $ 3.93 B | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 3.59 | -1.1 % | $ 1.07 B |  Canada |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
366 M | $ 20.5 | 3.22 % | $ 2.59 B | USA |
 |
Aptorum Group Limited
APM
|
62.2 K | $ 0.81 | -1.57 % | $ 4.42 M | China |
 |
ANI Pharmaceuticals
ANIP
|
222 M | $ 75.14 | -1.82 % | $ 1.45 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
109 K | $ 1.57 | -3.68 % | $ 401 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
Athersys
ATHX
|
739 K | - | 3.77 % | $ 22.4 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
9.81 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
224 M | $ 163.09 | -0.61 % | $ 8.11 B | USA |
 |
Champions Oncology
CSBR
|
11.2 M | $ 6.0 | - | $ 82 M | USA |
 |
BridgeBio Pharma
BBIO
|
139 M | $ 65.5 | -1.57 % | $ 12.5 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
312 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
56.9 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
865 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
205 K | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
18.5 M | - | -7.31 % | $ 87 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
908 M | $ 60.3 | -0.22 % | $ 11.6 B | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
800 K | $ 3.04 | -5.0 % | $ 1.09 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
812 K | $ 0.59 | - | $ 549 K |  Israel |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M | Israel |